Hendrika M. Oosterkamp

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer

Juliane Hannemann, Hendrika M. Oosterkamp, Cathy A.J. Bosch et al. · Journal of Clinical Oncology · 2005 · 206 citations · Full text

Medicine, Oncology, Pharmacology +16

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer et al. · The Lancet Oncology · 2017 · 158 citations

Medicine, Endocrinology, Pharmacology +14

Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Lale Erdem‐Eraslan, Martin J. van den Bent, Youri Hoogstrate et al. · Cancer Research · 2016 · 99 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z)

Hendrika M. Oosterkamp, Linda Scheiner, Maria C. Stefanova et al. · International Journal of Cancer · 1997 · 66 citations · Full text

Life Sciences, Molecular Biology, Oncology +13